Stocks Teva Pharmaceutical Industries Ltd

More

  • Dec 9- An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's. The panel voted unanimously that the drug should not be approved for children aged 12 to 17.. The FDA is not required to follow the advice of its expert advisory panels, but typically does so.

  • Teva gets U.S. FDA approval for cancer drug Tuesday, 8 Dec 2015 | 7:22 AM ET

    Dec 8- Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva, which has licensed the...

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • Nov 12- Generic drug maker Mylan NV's $26 billion hostile bid for peer Perrigo Company Plc looked unlikely to succeed late on Thursday, a few hours before it was set to expire, according to people familiar with the matter. If confirmed, the outcome would represent a major victory for Perrigo's defiant Chief Executive Joseph Papa, and a bitter blow to Mylan's...

  • WASHINGTON, Nov 6- The U.S. Supreme Court, taking up a new challenge to President Barack Obama's signature healthcare law, will decide whether religious groups should be freed from a mandate that contraception coverage be provided in employee health insurance plans. The Supreme Court narrowly rejected two major conservative challenges to the law in 2012 and,...

  • That could ease concern that if Allergan Inc's "friendly" talks with Pfizer Inc end in a merger, the combined company may not remain one of the world's largest inventors of new medicines. Pfizer refused to comment on Saunders' role in any potential deal with Allergan. Pfizer board member Dennis Ausiello, chief of medicine at Massachusetts General Hospital in...

  • Nov 6- A Pfizer Inc merger with Ireland- based Allergan, in addition to providing tax benefits, would bolster the U.S. drugmaker's growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent. "This would be the creation of two companies really, not one huge $350 billion Pfizer," Andy Summers, co-portfolio manager at Janus...

  • Oct 29- Pfizer Inc, the No. 1 U.S. drugmaker, and Botox maker Allergan Plc said they were in friendly talks to create a pharmaceutical colossus but the prospect that the company would seek to avoid U.S. taxes sounded political alarm bells. Both New York- based Pfizer and Dublin- based Allergan said no agreement has been reached and declined to discuss any terms of the...

  • Oct 29- Botox maker Allergan Plc and Pfizer Inc on Thursday said they were in early, friendly talks to create the world's largest drugmaker and potentially set up Pfizer to take advantage of Ireland's lower tax rates. Both New York- based Pfizer and Dublin- based Allergan said no agreement has been reached and declined to discuss any terms. Allergan shares jumped 8...

  • Oct 29- Botox maker Allergan Plc and Pfizer Inc on Thursday said they were in early, friendly talks to create the world's largest drugmaker and potentially set up Pfizer to take advantage of Ireland's lower tax rates. Both New York- based Pfizer and Dublin- based Allergan said no agreement has been reached and declined to discuss any terms. Allergan shares jumped 8...

  • Allergan confirms talks on possible deal with Pfizer Thursday, 29 Oct 2015 | 11:57 AM ET
    Pfizer headquarters in New York.

    A possible deal between Ireland-based Allergan and U.S. drugmaker Pfizer raises questions about another pharmaceutical tax inversion.

  • UPDATE 2-Pfizer, Allergan say in talks on merger Thursday, 29 Oct 2015 | 10:36 AM ET

    Oct 29- Botox maker Allergan Plc and Pfizer Inc on Thursday confirmed they were in preliminary, friendly talks on a potential merger, a deal that would create the world's largest drugmaker. Both Pfizer and Ireland- based Allergan said no agreement has been reached and declined to discuss any terms that might lead to such a tie-up. Allergan shares jumped 8.2...

  • *Pfizer and Allergan decline to comment. A bid for Allergan, which has a market value of $113 billion, would be Pfizer's second recent attempt to acquire a big rival, following its unsuccessful courtship last year of Anglo-Swedish pharmaceuticals group AstraZeneca Plc. Combining Allergan and Pfizer, which is worth $219 billion, would create the world's largest...

  • Oct 28- Pharmaceutical giant Pfizer Inc recently approached Botox-maker Allergan Plc to discuss what could be the biggest takeover deal this year, the Wall Street Journal said on Wednesday, citing people familiar with the matter. A bid for Allergan, which has a market value of $113 billion, would be Pfizer's second attempt to acquire a European rival, following...

  • Oct 28- Drugmakers Pfizer Inc and Allergan Plc are considering combining in what could be the biggest merger in the healthcare industry in already busy year, the Wall Street Journal said on Wednesday. Pfizer recently approached botox-maker Allergan about a deal, the Journal said, citing people familiar with the matter. Both Pfizer and Allergan's shares were...

  • Oct 8- Neurocrine Biosciences Inc's experimental drug for tardive dyskinesia, a neurological disorder, was effective in a late-stage study, bringing it a step closer to becoming the first treatment to win U.S. approval for the condition. About 10 percent of the 6 million U.S. patients who are currently on antispychotics develop tardive dyskinesia, Leerink...

  • Powered by China, Asia overtakes Europe in M&As Tuesday, 6 Oct 2015 | 9:26 PM ET

    Despite economic uncertainties, M&A targets in Asia totaled $770.9 billion, overtaking Europe as the second most active region, after the U.S.

  • TEL AVIV, Oct 1- Teva Pharmaceutical Industries has struck a deal to buy Mexican drugmaker Representaciones e Investigaciones Médicas SA for $2.3 billion to strengthen its presence in Latin America. It is Teva's second major acquisition in recent months; in late July it agreed to pay $40.5 billion in cash and stock for Allergan's generics drug business to...

  • Sept 24- GlaxoSmithKline Plc said the European health regulator had recommended an approval for its injectable drug to treat asthma patients who don't respond well to traditional inhalers. GSK and other drugmakers including AstraZeneca Plc, Roche Holding AG, Teva Pharmaceutical Industries Ltd and Sanofi SA are developing drugs that take a more...